Neuro-Oncologist @SmilowCancer @YaleCancer | Assistant Professor of Clinical Neurology @YaleMed | Associate Director of the Neuro-Oncology Fellowship Program
Honored to share my deeply personal piece in the @NEJM . Molly’s story, her love of tutus, and her enduring legacy remind me daily of the importance of compassionate, family-centered care. #grief#childloss
https://t.co/z0z3AzJGM7
The Neuro-Oncology Academy announces SNO Grand Rounds Series Webinar: Advances in CAR-T Cell Therapies for Glioma
June 13, 2024, 11:00 AM ET.
Earn free CME!
Register today: https://t.co/BvjgXwlHVB
New in @JTOonline from Dr @brandon_imber:
Intracranial response to #osimertinib is excellent for pts with #EGFR-mutant #NSCLC#lcsm with de novo, previously untx brain metastases. Low local failure rates support upfront osimertinib alone in selected pts.
https://t.co/bBfZug9Zli
1/
A 68 yo M presented with days of confusion followed by increased somnolence.
An MRI was performed and demonstrated a splenial diffusion restricting lesion
What’s the differential.... and should he get steroids?
📣 Residents applying to Neuro-Oncology fellowship programs, save the date! The @NeuroOnc Adult Fellowship Educational Webinar on 12/14 will help guide the way! Click the link below for more information and to register.
https://t.co/cZ9BHfehw4
René Leriche said every physician carries within themselves a small cemetery where from time to time they go to pray
But you can also hold these people in your heart, in a place where you can return to celebrate them with their families (red was this patient’s favorite color 🎈)
Late breaking at #ASCO23: Mutations in isocitrate dehydrogenase 1 or 2 are common in low-grade glioma. The IDH inhibitor vorasidenib improved progression-free survival as compared with placebo. Full results of the INDIGO trial: https://t.co/qypyIPmdD0
@PCChemTweets@ProvidenceCol Congratulations! ACS Spring 2009 and 2010 with PC Chem were my first ever scientific meetings. An educational experience and A LOT of fun. Great memories.